3SBio Inc. (FRA:83B)

Market Cap	3.48B
Revenue (ttm)	1.21B
Net Income (ttm)	276.61M
Shares Out	n/a
EPS (ttm)	0.11
PE Ratio	12.59
Forward PE	n/a
Dividend	0.03 (2.03%)
Ex-Dividend Date	Jul 21, 2025

Volume	432
Average Volume	173
Open	1.450
Previous Close	1.470
Day's Range	1.450 - 1.460
52-Week Range	0.570 - 1.520
Beta	n/a
RSI	60.26
Earnings Date	May 9, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 5,577
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 83B

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY